3-(Hydroxy or hydroxymethyl)-6-methyl-5-(4-pyridinyl)-2(1H)-pyridinone and cardiotonic use thereof
AssigneeSterling Drug Inc.
InventorsGeorge Y. Lesher, Richard E. Philion
Life of this patent
Estimating the term…
Loading patent…
AssigneeSterling Drug Inc.
InventorsGeorge Y. Lesher, Richard E. Philion
Estimating the term…
3-(Hydroxy or hydroxymethyl)-6-methyl-5-(4-pyridinyl)-2(1H)-pyridinone or pharmaceutically acceptable acid-addition salt thereof is useful as a cardiotonic agent. 3-Hydroxy-6-methyl-5-(4-pyridinyl)-2(1H)-pyridinone is prepared by autoclaving a mixture of a sodium or potassium lower-alkoxide, a lower-alkanol and 3-(chloro or bromo)-6-methyl-5-(4-pyridinyl)-2(1H)-pyridinone and acidifying the reaction mixture. 3-Hydroxymethyl-6-methyl-5-(4-pyridinyl)-2(1H)-pyridinone is prepared by reacting 6-methyl-5-(4-pyridinyl)-2(1H)-pyridinone with excess formaldehyde at an acidic pH. Said 3-(hydroxy or hydroxymethyl)-6-methyl-5-(4-pyridinyl)-2(1H)-pyridinone or pharmaceutically acceptable acid-addition salt thereof is disclosed as the active ingredient in cardiotonic compositions for increasing cardiac contractility and in the method for increasing cardiac contractility in a patient requiring such treatment.
3-(Hydroxy or hydroxymethyl)-6-methyl-5-(4-pyridinyl)-2(1H)-pyridinone or pharmaceutically acceptable acid-addition salt thereof.
3-Hydroxy-6-methyl-5-(4-pyridinyl)-2(1H)-pyridinone or pharmaceutically acceptable acid-addition salt thereof.
3-Hydroxymethyl-6-methyl-5-(4-pyridinyl)-2(1H)-pyridinone or pharmaceutically acceptable acid-addition salt thereof.
A cardiotonic composition for increasing cardiac contractility, said composition comprising a pharmaceutically acceptable inert carrier and, as the active component thereof, a cardiotonically effective amount of 3-(hydroxy or hydroxymethyl)-6-methyl-5-(4-pyridinyl)-2(1H)-pyridinone or pharmaceutically acceptable acid-addition salt thereof.
The method for increasing cardiac contractility in a patient requiring such treatment which comprises administering orally or parenterally in a solid or liquid dosage form to such patient a cardiotonically effective amount of 3-(hydroxy or hydroxymethyl)-6-methyl-5-(4-pyridinyl)-2(1H)-pyridinone or pharmaceutically acceptable acid-acceptable salt thereof.
Dependencies are inferred from the claim text.